Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform

[1]  K. Blennow,et al.  Blood biomarkers for Alzheimer’s disease in clinical practice and trials , 2023, Nature Aging.

[2]  Huifu Wang,et al.  The dynamics of plasma biomarkers across the Alzheimer’s continuum , 2023, Alzheimer's Research & Therapy.

[3]  James G. Bollinger,et al.  The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review , 2022, Alzheimer's Research & Therapy.

[4]  M. Plebani,et al.  Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer’s disease , 2022, Clinical chemistry and laboratory medicine.

[5]  K. Blennow,et al.  Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[6]  A. Nairn,et al.  Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease , 2022, Alzheimer's Research & Therapy.

[7]  K. Blennow,et al.  Clinical performance and robustness evaluation of plasma amyloid‐β42/40 prescreening , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[8]  M. Carrillo,et al.  The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[9]  M. Gorno-Tempini,et al.  Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration , 2022, Neurology.

[10]  K. Blennow,et al.  The accuracy and robustness of plasma biomarker models for amyloid PET positivity , 2022, Alzheimer's research & therapy.

[11]  Keith A. Johnson,et al.  Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. , 2022, JAMA neurology.

[12]  Lin F. Yang,et al.  Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 , 2022, The Lancet. Public health.

[13]  K. Blennow,et al.  Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[14]  K. Blennow,et al.  Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid , 2021, Clinical chemistry and laboratory medicine.

[15]  P. Sánchez-Juan,et al.  Sleep Time Estimated by an Actigraphy Watch Correlates With CSF Tau in Cognitively Unimpaired Elders: The Modulatory Role of APOE , 2021, Frontiers in Aging Neuroscience.

[16]  K. Blennow,et al.  Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology , 2021, Acta Neuropathologica.

[17]  Nick C Fox,et al.  Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays , 2021, Alzheimer's & dementia.

[18]  Patrick J. Lao,et al.  Plasma p‐tau181, p‐tau217, and other blood‐based Alzheimer's disease biomarkers in a multi‐ethnic, community study , 2020, medRxiv.

[19]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[20]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[21]  Bradford C. Dickerson,et al.  Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration , 2020, Nature Medicine.

[22]  I. Santana,et al.  Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[23]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[24]  J. Clarimón,et al.  Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse , 2019, Annals of clinical and translational neurology.

[25]  C. Jack,et al.  Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography , 2018, Alzheimer's & Dementia.

[26]  Keith A. Johnson,et al.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers , 2016, Neurology.

[27]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[28]  K. Blennow,et al.  Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[29]  S. Engelborghs,et al.  Biobanking of CSF: international standardization to optimize biomarker development. , 2014, Clinical biochemistry.

[30]  Giovanni B. Frisoni,et al.  The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers , 2011, Alzheimer's & Dementia.

[31]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[32]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[33]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[34]  J. Trojanowski,et al.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. , 2010, Archives of neurology.

[35]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[36]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[37]  Charles DeCarli,et al.  Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? , 2003, Archives of neurology.

[38]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[39]  S. Folstein,et al.  “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .

[40]  M. Albert,et al.  Introduction to Revised Criteria for the Diagnosis of Alzheimer ’ s Disease : National Institute on Aging and the Alzheimer Association Workgroups , 2011 .

[41]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..